Skip to main content
Clinical Trials/NCT02116192
NCT02116192
Completed
Not Applicable

Early Intervention and Prevention of Non-Alcoholic Fatty Liver Disease in Adolescents

University of Wisconsin, Madison1 site in 1 country28 target enrollmentApril 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Non-alcoholic Fatty Liver Disease
Sponsor
University of Wisconsin, Madison
Enrollment
28
Locations
1
Primary Endpoint
Hepatic triglyceride content measured by Magnetic resonance (MR) PDFF
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This research study intends to learn about whether early intervention can help to prevent non-alcoholic fatty liver disease (NAFLD) in adolescents. Potentially eligible adolescents who are seen at the University of Wisconsin (UW) Pediatric Fitness Clinic will be asked to join the study. Patients who agree to participate in the study will be randomized into either the intervention group or the control group. The intervention group will follow a low-fructose diet. In addition, participants will be asked to return to the clinic for 4 follow-up visits during a 6-month interval.

Detailed Description

This will be a prospective, randomized, controlled trial for obese adolescents. Sixty obese youth (male and female), age 11-17 years with BMI \>95 %tile for age and sex and one parent/guardian will be recruited for inclusion into the study at an initial pediatric fitness clinic visit. Consented subjects will be stratified by gender and ethnicity and randomized into low fructose or standard weight loss dietary intervention groups.

Registry
clinicaltrials.gov
Start Date
April 2014
End Date
October 2017
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • 11-17 years of age
  • BMI \>95%tile for age and sex
  • Being seen for an initial clinic visit at the UW Pediatric Fitness Clinic
  • Parent willing to participate in study

Exclusion Criteria

  • History of chronic disease that effects hepatic or renal function including: Type 1 or Type 2 diabetes mellitus, known liver disease or other chronic illness.

Outcomes

Primary Outcomes

Hepatic triglyceride content measured by Magnetic resonance (MR) PDFF

Time Frame: 6 months

Secondary Outcomes

  • PNPLA3 genotype(6 months)
  • Novel free breathing hepatic MR PDFF protocol(6 months)
  • Metabolic biomarkers(6 months)

Study Sites (1)

Loading locations...

Similar Trials